Everand Logo

Welcome to Everand!

  • STAT

    Two Ebola treatments yield ‘substantial decrease’ in mortality, landmark trial shows

    Final data from a landmark clinical trial of four Ebola therapies conducted in the current outbreak in the DRC showed two of the drugs dramatically reduced the risk of dying…
    by Helen Branswell Nov 27, 2019 4 minutes
    Health workers wearing protective gear check on a mother of four whose husband died of Ebola at a treatment center in Beni, Congo.

    Final data from a landmark clinical trial of four Ebola therapies conducted in the current outbreak in the Democratic Republic of the Congo show two of the drugs dramatically reduced the risk of dying from the disease, especially in people who started treatment quickly after onset of their illness.

    Findings of the PALM trial, published in the New England Journal of Medicine on Wednesday, show that two treatments based on Ebola antibodies led to a survival rate of about 65% in treated patients, compared to 33% in the outbreak overall.

    Put another way, about 35% of the patients treated with a monoclonal antibody cocktail called REGN-EB3 made by Regeneron Pharmaceuticals

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
    The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
    New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

    Related